

# IMPORTANT NOTICE - WARNING RE FINANCIAL PROMOTIONS

---

**The content of this presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purposes of engaging in any investment activity may expose an individual to significant risk of losing all of the property or other assets involved.**

## ***Disclaimer***

This presentation is exempt from the general restriction in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds it is made exclusively to persons believed on reasonable grounds to be either (i) 'high net worth individuals' within the meaning of Article 48 of the Financial Services and Markets Act (Financial Promotion) Order 2005 ('FinProm'), or (ii) 'self-certified sophisticated investors' within the meaning of Article 50A FinProm.

If you are in any doubt about the investment to which this presentation relates, you are strongly recommended to consult an appropriately authorised financial adviser qualified to give advice in relation to an investment in [unquoted shares issued by single companies]. An investment in Occuity will not necessarily be suitable for all recipients of this presentation.



# Revolutionary Optical MedTech

A window on your health

**Mark Jenkins**

Chief Commercial Officer

[www.occuity.com](http://www.occuity.com)



## Our Mission

---

To improve the lives of hundreds of millions of people by developing  
painless, contact free **screening** & **monitoring** solutions for health  
conditions such as:

**GLAUCOMA**

**MYOPIA**

**DIABETES**

**ALZHEIMER'S**

**SEPSIS**

# Occuity: Strategy

## TECH PLATFORM

**15 PATENTS**  
14 PATENT FAMILIES GRANTED | 1 PATENT PENDING

**Additional R&D, IP & Patents**  
6 PATENTS IN DRAFT

## COMPETITIVE ADVANTAGE



Optical



Non-Contact



No Consumables



Handheld

## MARKETS

**Ophthalmic Products**  
\$5Bn

**Glucose Monitoring**  
\$17Bn

**Disease Screening**  
\$20Bn

## ADDRESSING

GLAUCOMA

MYOPIA

DIABETES

DIABETES

SEPSIS

ALZHEIMER'S

## PRODUCT PIPELINE

PM1



AX1



INDIGO



SD1



## PM1 Pachymeter

The world's first handheld, optical pachymeter



***Measure  
Corneal Thickness...  
in seconds***



# Myopia



**50%** - of the world's population will have myopia by 2050



Almost **1 BILLION** people will be high myopes by 2050



**High Myopia** – 1/10 people with high myopia go blind

Measuring axial length is key to monitoring myopia progression

## AX1 Axiometer™

---

The world's first handheld, optical  
axial length meter

***Measure Axial Length...  
in seconds***



# AX1 Aximeter™ - Specifications

Specification	Measurement
Axial length measurement range	18 - 32mm
Diopetre range	+2 to -15
Resolution	1um
Precision	10um
Measurement Time (per eye)	<10s
Measurement scan rate	200 measurements per second
Wavelength	1310nm/850nm





occuity


# AX1 Axiometer™

measure axial length in seconds

Watch Video



# AX1 Axiometer™ - Data Transfer



**Occuity mEyeGuide Scanner**  
Powered by **Occumetra**

NAME  
Test PATIENT

AGE (6-18)  
8

SEX  
**Male** Female

ETHNICITY  
White

LEFT EYE (OS)  
SPHERE - 4.75 CYLINDER - .75  
AXIS 175

RIGHT EYE (OD)  
SPHERE - 5 CYLINDER - .5  
AXIS 180

**Scan Axial Length Data**



## AX1 Axiometer™ - Roadmap

---

- Current prototypes showing good correlation against Lenstar and IOL Master
- Clinicals end of year
- Submission to UKCA/FDA/CE – early next year
- Expected UKCA – Early summer 2026 – others to follow



# Market Progress: Ophthalmic Products

## Establishing Global Distributor Network


- 19 signed
- 6 awaiting registration
- Many others in discussion

## PM1 - **ON MARKET** - Revenue

- Market price - £3,995
- Market Estimate – 1,000 units pa

## AX1 Revenue

- Market price – c. £8,000
- Market Estimate – 10,000 units pa






# OCULOMICS

---

*The science of analysing **biomarkers in the eye** to  
diagnose predict and understand **systemic diseases**  
throughout the body*



# Future: Glucose Monitoring

## Diabetes

- Goal: Replace invasive blood testing with a simple pain free scan of the eye
- Intend to be the world's first non-invasive glucose meter for diabetes management
- Promising early clinical results
- Latest prototype working *in-vitro*

Occuity Indigo™ 2029



Concept Visual

# Future: Disease Screening

---

## Diabetes

- Goal: Identify diabetic / pre-diabetic / healthy – before symptoms
- Prototype already identifying diabetic state

## Alzheimer's

- Goal: Early detection to enable early treatment
- Building on diabetes technology
- Grant funded project



## Funding Round Financials

---

- Funding to date of £9m + £4m Grants
  - Last Round - PMV: £24m - £5m raised
- Current Round: £2.0m+ Equity
  - PMV: £35m
  - EIS qualifying
  - Hard Commitment: £500k+
    - Further Soft Commitment: £500k
  - Now open on Crowdcube





## Summary:

---



**Disruptive Optical platform technology – 15 Patents**

**Competitive Advantage: Non-invasive | Handheld | No consumables**



**PM1 - Generating Revenues**

**AX1 – Huge Opportunity to follow**



**Strategic Roadmap of Future Opportunities - Screening & Monitoring**

**Multiple markets - MRR model + Data monetisation**

## Find Out More:

---

[www.occuity.com/escrs-2025](http://www.occuity.com/escrs-2025)



**StartUp  
Awards**



Royal Academy  
of Engineering

**IOP**  
Institute of Physics

**IET** The Institution of  
Engineering and Technology

